IONpath, Inc., a Menlo Park, Calif.-based developer of high-definition spatial proteomics, closed a $18m Series B financing.
The round was led by Samsara BioCapital, with participation from new investor Bruker Corporation, and existing major investors Genoa Ventures, ND Capital, Paladin Partners Investments, Trancos IONpath Investors, Norwich Ventures, and Vertical Venture Partners Growth Fund.
The company intends to use the funds to continue to expand operations and its business reach.
Led by Sander Gubbens, PhD, CEO, IONpath is a developer of high-definition spatial proteomics, innovating tissue imaging and analysis to accelerate medical discovery and improve human health. Its multiplexed ion beam imaging) platform enables a deeper understanding of the tissue microenvironment with multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, the company provides actionable insights to translational and clinical researchers at pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.